Benitec Biopharma Inc

Chart & Performance

D1W1MN

P/E

—

P/S

1,387.69

EPS

—

Div Yield, %

—

Shrs. gr., 5y

140.56%

Rev. gr., 5y

-54.69%

Revenues

216k

+188.00%

Net income

-22m

L+11.19%

CFO

-19m

L+7.72%

Dividend

Jun 01, 20180.003 USD/sh

Earnings

May 12, 2026

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

URL

https://benitec.com/

IPO date

Jul 11, 2012

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2025‑06	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06	2017‑06	2016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT